The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the United States District Court for the Southern District of New York on behalf of investors who purchased Nextcure, Inc. (NASDAQ: NXTC) securities: (1) between November 5, 2019 and July 14, 2020, inclusive; and/or (2) pursuant or traceable to the company’s secondary public offering declared effective on November 14, 2019.
According to the Nextcure lawsuit, throughout the class period, defendants’ statements were materially misleading because the data Defendants possessed on its principle product candidate, NC318, showed a lack of efficacy and objective responses. Had the truth been revealed, the market would have seen that NC318 was not, in fact, effective in treating most tumor types, that the NC318 application was proving to be limited (if even useful at all), and, as a result, there was a significant realizable risk that NC318 would not be nearly as popular as then-existing blockbuster drugs, such as Keytruda.
If you suffered a loss in Nextcure you have until November 20, 2020 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
To receive more information, please fill out the form.